ÐÓ°ÉÂÛ̳

Skip to main content
Quest Diagnostics

Estimated SARS-CoV-2 Antibody Seroprevalence Trends and Relationship to Reported Case Prevalence From a Repeated, Cross-sectional Study in the 50 States and the District of Columbia, United States-October 25, 2020¨CFebruary 26, 2022

Authors:?Wiegand RE, Deng Y, Deng X, Lee A, Meyer WA 3rd, Letovsky S, Charles MD, Gundlapalli AV, MacNeil A, Hall AJ, Thornburg NJ, Jones J, Iachan R, Clarke KEN.

Citation: Lancet Reg Health Am. 2023 Feb;18:100403. doi: 10.1016/j.lana.2022.100403. Epub 2022 Dec 2.

Specialties:?Infectious Disease, ÐÓ°ÉÂÛ̳-19, Immunology

Download key summary

Related content

Test FAQ
SARS CoV 2 Antibody Testing
Publication
Assessing vulnerability to ÐÓ°ÉÂÛ̳ 19 in high risk populations: the role of SARS CoV 2 spike targeted serology
Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent ÐÓ°ÉÂÛ̳-19-Related Outcomes

Our company

Quest? is the brand name used for services offered by ÐÓ°ÉÂÛ̳ and its affiliated companies. ÐÓ°ÉÂÛ̳ and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.? Other affiliates operated under the Quest? brand, such as Quest Consumer Inc., do not provide HIPAA-covered services.?

?

Quest?, Quest Diagnostics?, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks¡ª? and ?¡ªare the property of their respective owners. ? 2025 ÐÓ°ÉÂÛ̳. All rights reserved. Image content features models and is intended for illustrative purposes only.